US FDA Facility Records Review Evolved Into More Formal Process As Pandemic Continued
With more experience, the US FDA was able to standardize record review requests and timing.
You may also be interested in...
Video facility tours expected to help clear way for timely drug and biologic approvals while COVID-19 still prevents inspections.
Last year was not the greatest performance by the agency outside of COVID-19, Richard Pops tells BIO conference.
FY2020 review highlights drop in inspections, preparations for growing backlog, and pandemic test of Janet Woodcock’s 21st Century proposition – developments that will likely reverberate in the years ahead.